Study on how cancer treatment affects women's sexual and reproductive health

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This observational study aims to investigate the impact of cancer treatments on the sexual and reproductive health of women diagnosed with breast cancer and lymphoma. Participants will complete surveys and may opt for blood draws to assess ovarian function and fertility. The study focuses on premenopausal women who are either newly diagnosed or undergoing treatment for early-stage breast cancer or aggressive lymphoma. The research will help understand the long-term effects of cancer therapies on women's reproductive health.

Why it matters

Who can join: the full rules

Inclusion Criteria:

Subject Inclusion Criteria for Cohort of Premenopausal Women with Early Stage Breast Cancer and Lymphoma

* Women, 18 years of age and older
* Premenopausal women at time of diagnosis who have either been pregnant or had at least one menstrual period in the last 12 months

  * Note: premenopausal women at time of diagnosis who have not been pregnant or have not had at least one menstrual period in the last 12 months are able to participate only if they have had an intrauterine device (IUD) in place within the last 12 months.
* Women with newly diagnosed breast cancer (stage 0-III) who are within 1 month of starting systemic treatment or women with any aggressive lymphoma being treated with first line therapy with curative intent.
* Breast cancer patients with any receptor type
* English speaking
* Able to participate in the informed consent process

Subject Inclusion Criteria for Tamoxifen Only Subset of Cohort of Premenopausal Women with Early Stage Breast Cancer and Lymphoma

* Women, 18 years of age and older.
* Premenopausal women at time of diagnosis who have either been pregnant or had at least one menstrual period in the last 12 months

  * Note: premenopausal women at time of diagnosis who have not been pregnant or have not had at least one menstrual period in the last 12 months are able to participate only if they have had an intrauterine device (IUD) in place within the last 12 months.
* Women with newly diagnosed breast cancer (stage 0-III) who have not yet started treatment and are planning to start Tamoxifen as their only form of systemic treatment within one month
* Breast cancer patients with any receptor type
* English speaking
* Able to participate in the informed consent process

Subject Inclusion Criteria for Cohort of Postmenopausal Women with Early Stage Breast Cancer and Lymphoma

* Women, 18 years of age and older.
* Postmenopausal women at time of diagnosis who have been without period for ≥ 2 years.
* Women with newly diagnosed breast cancer (stage 0-III) who are within 1 month of starting systemic treatment or women with any aggressive lymphoma being treated with first line therapy with curative intent.
* Breast cancer patients with any receptor type
* English speaking
* Able to participate in the informed consent process

Exclusion Criteria:

Subject Exclusion Criteria for both Pre and Postmenopausal Women with Early Stage Breast Cancer and Lymphoma

* Active secondary cancer requiring cytotoxic chemotherapy
* Prior systemic treatment for a malignancy

Where it's running

• Memorial Sloan Kettering Basking Ridge
  Basking Ridge, New Jersey, United States Recruiting
• Memorial Sloan Kettering Monmouth
  Middletown, New Jersey, United States Recruiting
• Memorial Sloan Kettering Bergen
  Montvale, New Jersey, United States Recruiting
• Memorial Sloan Kettering Commack
  Commack, New York, United States Recruiting
• Memorial Sloan Kettering Westchester
  Harrison, New York, United States Recruiting
• Memorial Sloan Kettering Cancer Center
  New York, New York, United States Recruiting

Study contacts

• Principal investigator: Shari Goldfarb, MD — Memorial Sloan Kettering Cancer Center
• Study coordinator: Shari Goldfarb, MD
• Phone: 646-888-5080

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• 18F-G1 PET/CT to see early immunotherapy response in solid tumors and blood cancers

  We are testing if the 18F-G1 PET/CT scan can help tell early on whether people with solid tumors or blood cancers will respond to immunotherapy.

  Recruiting Peking University First Hospital · Beijing · NCT07039474

• Personalized nutrition and exercise program for cancer survivors

  This study is testing whether a personalized nutrition and exercise program can help breast, prostate, or colorectal cancer survivors eat healthier and be more active.

  Recruiting University of Miami · Miami, Florida · NCT06534918

• Helping adolescent and young adult cancer survivors manage symptoms and stay engaged in post-treatment care

  This trial will test whether AYA STEPS, a six-session digital program, can help adolescent and young adult cancer survivors reduce symptoms and keep up with recommended follow-up care.

  Recruiting Duke University · Durham, North Carolina · NCT06371768

• Exploring the unmet needs of cancer survivors in Reggio Emilia

  This study is trying to find out what cancer survivors need most after finishing their treatment to help improve their care and quality of life.

  Recruiting University of Modena and Reggio Emilia · Reggio Emilia, Reggio Emilia · NCT06236373

• Digital peer support for young adults with cancer

  This study is testing a digital support program to see if it can help young adults who have finished cancer treatment by connecting them with trained peers for guidance and encouragement.

  Recruiting University Health Network, Toronto · Toronto, Ontario · NCT06193369

• Improving heart function in cancer patients using vagus nerve stimulation

  This study is testing whether a small device that stimulates the vagus nerve can help improve heart function in cancer patients who have recently received chemotherapy.

  Recruiting at 2 sites Early Phase 1 University of Oklahoma · Oklahoma City, Oklahoma and 1 other locations · NCT05921253

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.